Ocular Surface, published by Elsevier, stands at the forefront of ophthalmology research, with a notable Impact Factor reflecting its significant contribution to the field. As a vibrant platform for disseminating cutting-edge findings, this journal has achieved Q1 ranking in the Ophthalmology category as of 2023, placing it amongst the top-tier journals globally, specifically ranking 4th out of 137 in Scopus with an impressive 97th percentile. Spanning across the years from 2003 to 2024, Ocular Surface focuses on advancing knowledge in areas such as ocular pathology, therapy, and surgical interventions. While the journal is not open access, it provides invaluable insights and empirical data essential for researchers, professionals, and students dedicated to improving ocular health. With an address rooted in Amsterdam, Netherlands, this esteemed journal continues to enrich the global conversation in ophthalmology.

EXPERIMENTAL EYE RESEARCH, published by Academic Press Ltd - Elsevier Science Ltd, is a preeminent journal dedicated to advancing the fields of ophthalmology and neuroscience. With a history of insightful publications dating back to 1961, this journal serves as a critical platform for researchers, professionals, and students interested in the cellular and molecular mechanisms underlying visual processes. The journal boasts impressive rankings, including being placed in the top quartile (Q1) of both the Ophthalmology and Sensory Systems categories, and is recognized in the 2nd quartile (Q2) for Cellular and Molecular Neuroscience. With an impact factor reflecting its significant contribution to the field, EXPERIMENTAL EYE RESEARCH is a valuable resource that promotes the exchange of innovative research and ideas essential for understanding the complexities of eye function and vision-related disorders. Researchers looking to publish their findings or stay abreast of the latest studies will find this journal a vital component of their academic toolkit.

The Journal of Ophthalmic & Vision Research, published by KNOWLEDGE E, stands as a crucial platform for disseminating high-quality research in the field of ophthalmology. With an ISSN of 2008-2010 and an E-ISSN of 2008-322X, this journal fosters open access to valuable insights since 2010, enhancing visibility and reach for researchers globally. Based in Dubai, UAE, it has established a reputation for excellence, reflected in its Q2 ranking in Ophthalmology for 2023 and its position among the top 65th percentile in Scopus. Covering a broad spectrum of topics within ophthalmic science, the journal serves as a vital resource for professionals, researchers, and students by presenting original research, reviews, and case studies that drive innovation and collaboration within the community. As the journal continues to contribute to advancements in eye care and vision sciences, it invites scholars to explore, engage, and publish within its pages, thus enriching the global discourse on ophthalmic health.

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Biologics-Targets & Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, specializing in the fields of Gastroenterology, Immunology and Allergy, Oncology, Pharmacology (Medical), and Rheumatology. Launched in 2007, the journal has established a solid reputation for disseminating high-quality research that bridges the gap between laboratory findings and clinical application, offering insights into the therapeutic potential of biologics. With a commendable impact factor and placement in Q1 quartiles across multiple medical domains in 2023, Biologics-Targets & Therapy ranks among the top journals in its categories, providing a platform for researchers and clinicians to share their latest discoveries. Researchers can access articles freely, promoting wider dissemination and collaboration in the scientific community. By publishing innovative studies and reviews, this journal plays a pivotal role in advancing the understanding and therapeutic applications of biologics, making it an essential resource for professionals and students alike.

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

Augenheilkunde Up2date is a pivotal journal in the field of ophthalmology, published by GEORG THIEME VERLAG KG, a renowned publisher known for its commitment to advancing medical knowledge. With its ISSN 1616-9719 and E-ISSN 1616-9735, this journal serves as a vital resource for researchers, professionals, and students interested in the latest developments and nuanced discussions in eye health. Although not available as open access, its curated content offers significant insights into contemporary research, clinical practices, and emerging trends in ophthalmology, thus promoting the continuous professional development of its readers. There is an emphasis on providing comprehensive reviews that encapsulate the pertinent advancements in the field, making it an essential publication for those aiming to enhance their expertise in eye care and vision science.

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.